New York, June 2, 2026, 16:01 (EDT)
LifeMD shares finished up Tuesday. The telehealth company tapped Umesh Sripad as CTO. Sripad has digital exec experience at PetMeds, IKEA USA and Bed Bath & Beyond. He’ll oversee AI, cybersecurity and data systems at LifeMD.
The shares closed 1.3% higher at $4.69 on Nasdaq, moving between $4.54 and $4.80 through the day. Google Finance listed the market cap close to $225 million.
LifeMD is trying to show it can grow from a small virtual-care shop into a larger subscription health business. The company said Monday that Sripad will run tech strategy, platform changes, AI, cybersecurity, data systems and scaling up operations.
LifeMD Chairman and CEO Justin Schreiber said the company operates a virtual primary, specialty care and pharmacy platform in all 50 states with nearly 350,000 patients. Schreiber called Umesh Sripad’s tech experience “invaluable.” Sripad said LifeMD was at “a pivotal moment.” Businessinsider
LifeMD said it granted 150,000 restricted stock units to Sripad as an inducement. Half will vest over three years, with the rest tied to meeting company performance goals. Restricted stock units give shares after certain conditions or timelines are met.
Wall Street traded near highs with little movement. Reuters market data had the Dow Jones Industrial Average up 0.46%, the S&P 500 up 0.13% and the Nasdaq Composite edging up just 0.01%. AI interest was offset by some caution around Middle East risks.
LifeMD’s platform push comes up against competition from Hims & Hers and Teladoc Health. Hims & Hers sells online care for weight loss, sexual health and more. Teladoc is in virtual care, mental health and chronic conditions. Both sets a high bar for how LifeMD handles tech and hangs onto patients, which may end up mattering more than who they just hired.
LifeMD’s last quarter offered a look at the numbers investors get. The company posted Q1 revenue of $50.2 million and said it had 365,004 active subscribers. Gross margin hit 88%. Adjusted EBITDA was a loss of $4.5 million. Adjusted EBITDA removes interest, taxes, depreciation, amortization, and certain other items from earnings.
LifeMD CFO Atul Kavthekar called out “strong subscriber momentum” last quarter and “early benefits of platform efficiency.” He said revenue topped the company’s $48 million to $49 million forecast. LifeMD kept its 2026 full-year revenue guidance at $220 million to $230 million and adjusted EBITDA at $12 million to $17 million. SEC
But there’s a risk that tech upgrades won’t bring cost relief fast. Selling and marketing expense jumped 34% to $29.9 million in the first quarter, and GAAP loss from continuing operations for common shareholders got bigger compared to last year. If patient-acquisition costs don’t fall or demand for weight management slips, making the case for profit in the second half is tougher.
Tuesday’s move stayed limited, not a breakout. The next question for the stock is if the new CTO can actually speed up product work, cut operating friction and help with retention. Those are the changes investors tend to pay for only once the results start to show in the numbers.
